These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 24397846)

  • 1. Iron chelation and multiple sclerosis.
    Weigel KJ; Lynch SG; LeVine SM
    ASN Neuro; 2014 Jan; 6(1):e00136. PubMed ID: 24397846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).
    Kontoghiorghes GJ; Pattichi K; Hadjigavriel M; Kolnagou A
    Transfus Sci; 2000 Dec; 23(3):211-23. PubMed ID: 11099897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deferiprone iron chelation as a novel therapy for experimental mucormycosis.
    Ibrahim AS; Edwards JE; Fu Y; Spellberg B
    J Antimicrob Chemother; 2006 Nov; 58(5):1070-3. PubMed ID: 16928702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Objectives and mechanism of iron chelation therapy.
    Hershko C; Link G; Konijn AM; Cabantchik ZI
    Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
    Barman Balfour JA; Foster RH
    Drugs; 1999 Sep; 58(3):553-78. PubMed ID: 10493280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic intracellular iron chelation combinations: mechanisms and conditions for optimizing iron mobilization.
    Vlachodimitropoulou Koumoutsea E; Garbowski M; Porter J
    Br J Haematol; 2015 Sep; 170(6):874-83. PubMed ID: 26033030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs.
    Kontoghiorghes GJ
    Toxicol Lett; 1995 Oct; 80(1-3):1-18. PubMed ID: 7482575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of iron chelation on R1 and R2 calibration curves in gerbil liver and heart.
    Wood JC; Aguilar M; Otto-Duessel M; Nick H; Nelson MD; Moats R
    Magn Reson Med; 2008 Jul; 60(1):82-9. PubMed ID: 18581418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells.
    Glickstein H; El RB; Shvartsman M; Cabantchik ZI
    Blood; 2005 Nov; 106(9):3242-50. PubMed ID: 16020512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
    Fischer R; Piga A; Harmatz P; Nielsen P
    Ann N Y Acad Sci; 2005; 1054():350-7. PubMed ID: 16339683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response.
    Aydinok Y; Evans P; Manz CY; Porter JB
    Haematologica; 2012 Jun; 97(6):835-41. PubMed ID: 22180427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current recommendations for chelation for transfusion-dependent thalassemia.
    Kwiatkowski JL
    Ann N Y Acad Sci; 2016 Mar; 1368(1):107-14. PubMed ID: 27186943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
    Hagag AA; Hamam MA; Taha OA; Hazaa SM
    Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats.
    Kontoghiorghes GJ; Sheppard L; Hoffbrand AV; Charalambous J; Tikerpae J; Pippard MJ
    J Clin Pathol; 1987 Apr; 40(4):404-8. PubMed ID: 3584483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis.
    Devos D; Cabantchik ZI; Moreau C; Danel V; Mahoney-Sanchez L; Bouchaoui H; Gouel F; Rolland AS; Duce JA; Devedjian JC;
    J Neural Transm (Vienna); 2020 Feb; 127(2):189-203. PubMed ID: 31912279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.
    Kontoghiorghes GJ; Eracleous E; Economides C; Kolnagou A
    Curr Med Chem; 2005; 12(23):2663-81. PubMed ID: 16305464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deferiprone, an orally deliverable iron chelator, ameliorates experimental autoimmune encephalomyelitis.
    Mitchell KM; Dotson AL; Cool KM; Chakrabarty A; Benedict SH; LeVine SM
    Mult Scler; 2007 Nov; 13(9):1118-26. PubMed ID: 17967839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of iron chelation therapy with desferrioxamine and deferiprone.
    Cappellini MD; Musallam KM; Taher AT
    Hemoglobin; 2009; 33 Suppl 1():S58-69. PubMed ID: 20001633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron-chelation therapy with oral deferiprone in patients with thalassemia major.
    Olivieri NF; Brittenham GM; Matsui D; Berkovitch M; Blendis LM; Cameron RG; McClelland RA; Liu PP; Templeton DM; Koren G
    N Engl J Med; 1995 Apr; 332(14):918-22. PubMed ID: 7877649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
    Taher A; Sheikh-Taha M; Koussa S; Inati A; Neeman R; Mourad F
    Eur J Haematol; 2001 Jul; 67(1):30-4. PubMed ID: 11553264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.